This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CNinsure's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Looking at our three major business lines, the net revenues of our P&C insurance segment witnessed a marginal decreases of 0.6% year-on-year, primarily due to increased market competition as insurance companies strengthened the investment in direct sales and telemarketing. Besides insurance companies have been increasing commissions paid to their direct sales channels, just we also need to increase commissions payout to our sales agents benchmarking the market level which further squeezed the profits out of our labor driven sales model and reduced the gross margin of our P&C insurance segment.

On the life insurance side, impacted by the weak performance in the life insurance industry our sales of new policies recorded a negative growth but the total net revenues derived from life insurance business was up nearly 9% from the year ago quarter, primarily driven by the increase in the sales of short-term health insurance and recurring commissions derived from regular premium insurance policies. Recurring premiums recorded a strong growth of 22.5% year-on-year for the second quarter of 2012. Claims adjusting business was relatively stable with net revenues up 7.9% from the year ago quarter, although its gross margin witnessed a slight decrease.

Behind the sudden (inaudible) long, rapid growth of the Chinese insurance market starting from 2011, is inherent efficiency in its expanses development model and industry is in a critical period of structural. In the meantime the regulatory body continues its effort to push the insurance industry in a sustainable and healthy way. Recently, the [CIC] issued a series of rules and regulations that allow insurance companies to broaden their investment scope and continuously launch products and service innovations in an effort to drive insurance companies to strengthen their core competencies in asset management and product design.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.01 1.05%
FB $99.75 -4.15%
GOOG $682.74 -0.12%
TSLA $147.99 -8.99%
YHOO $27.05 -3.29%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs